XSHE
300158
Market cap763mUSD
Oct 09, Last price
5.31CNY
1D
3.11%
1Q
8.37%
Jan 2017
-45.76%
IPO
-42.93%
Name
Shanxi Zhendong Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
1.90
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.46%
Rev. gr., 5y
-11.48%
Revenues
2.77b
-6.83%
Net income
-301m
L-77.34%
CFO
-448m
L+198.76%
Dividend
May 09, 20222.7 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is based in Changzhi, China.
Key people
Jianyong Zhan
Chief Financial Officer · since 2025
Rongli You
Vice President-R&D · since 2018
Jiawen Ai
Director · since 2024
Kun Li
Chairman of the Board, Acting Secretary of the Board · since 2025
Jing Li
Director · since 2021
Zhimin Wang
Director
Xufeng Wang
Vice President, Director · since 2024
Lianmin Yang
President, Director · since 2023
Lina Jin
Independent Director · since 2024
Wanliang Lu
Independent Director · since 2024
Xuemei Qin
Independent Director · since 2023
Headquarters & legal address
山西省长治县光明南路振东科技园
长治市, SX 100000
CN
长治市, SX 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||